The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders

Evans, Elizabeth; Hser, Yih‐Ing

doi:10.1007/978-3-030-16257-3_9

Cited by 4 publications

(2 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the chronic nature of OUD (Evans & Hser, 2019;Hser et al, 2015), the opioid epidemic will likely remain even as solutions to the COVID-19 pandemic develop. COVID-19 has exposed the need for criminal justice reforms (Mukherjee & El-Bassel, 2020;Nowotny et al, 2020).…”

Section: Lessons Learned and Future Directionsmentioning

confidence: 99%

COVID-19 and treating incarcerated populations for opioid use disorder

Donelan

Hayes

Potee

et al. 2021

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

The Franklin County Sheriff's Office (FCSO), in Greenfield, Massachusetts, is among the first jails nationwide to provide correctional populations with access to all three medications to treat. opioid use disorder (MOUD, i.e., buprenorphine, methadone, naltrexone). In response to the COVID-19 pandemic, FCSO quickly implemented comprehensive mitigation policies and adapted MOUD programming. Two major challenges for implementation of the MOUD program were the mandated rapid release of nonviolent pretrial individuals, many of whom were being treated with MOUD and released too quickly to conduct continuity of care planning; and establishing how to deliver physically distanced MOUD services in jail. FCSO implemented and adapted a hub-and-spoke MOUD model, developed telehealth capacity, and experimented with take-home MOUD at release to facilitate continuity-of-care as individuals re-entered the community. Experiences underscore how COVID-19 accelerated the uptake and diffusion of technology-infused OUD treatment and other innovations in criminal justice settings. Looking forward, to address both opioid use disorder and COVID-19, jails and prisons need to develop capacity to implement mitigation strategies, including universal and rapid COVID-19 testing of staff and incarcerated individuals, and be resourced to provide evidence-based addiction treatment. FCSO quickly pivoted and adapted MOUD programming because of its history of applying public health approaches to address the opioid epidemic. Utilizing public health strategies can enable prisons and jails to mitigate the harms of the co-occurring epidemics of OUD and COVID-19, both of which disproportionately affect criminal justice populations, for persons who are incarcerated and the communities to which they return.

show abstract

Section: Lessons Learned and Future Directionsmentioning

confidence: 99%

COVID-19 and treating incarcerated populations for opioid use disorder

Donelan

Hayes

Potee

et al. 2021

Journal of Substance Abuse Treatment

Self Cite

View full text Add to dashboard Cite

show abstract

“…Chronic pain and OUD are linked to biopsychosocial barriers to care that include limited access to medications, chronic unemployment, poverty, mental illness, stigma, social isolation, and poor social support ( 41 ). Socioeconomic marginalization is positively associated with overdose and prevalence rates ( 42 ).…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 pandemic on chronic pain and opioid use in marginalized populations: A scoping review

Choe

Zinn

Hoang

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

IntroductionThe COVID-19 pandemic has had a variable effect on vulnerable populations, including patients with chronic pain who rely on opioid treatment or have comorbid opioid use disorder. Limited access to care due to isolation measures may lead to increased pain severity, worse mental health symptoms, and adverse opioid-related outcomes. This scoping review aimed to understand the impact of the COVID-19 pandemic on the dual epidemics of chronic pain and opioids in marginalized communities worldwide.MethodsSearches of primary databases including PubMed, Web of Science, Scopus, and PsycINFO were performed in March 2022, restricting the publication date to December 1, 2019. The search yielded 685 articles. After title and abstract screening, 526 records were screened by title and abstract, 87 through full-text review, of which 25 articles were included in the final analysis.ResultsOur findings illuminate the differential distribution of pain burden across marginalized groups and how it serves to heighten existing disparities. Service disruptions due to social distancing orders and infrastructural limitations prevented patients from receiving the care they needed, resulting in adverse psychological and physical health outcomes. Efforts to adapt to COVID-19 circumstances included modifications to opioid prescribing regulations and workflows and expanded telemedicine services.ConclusionResults have implications for the prevention and management of chronic pain and opioid use disorder, such as challenges in adopting telemedicine in low-resource settings and opportunities to strengthen public health and social care systems with a multidisciplinary and multidimensional approach.

show abstract

Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

Evans

Yoo²,

Huang³

et al. 2019

Journal of Substance Abuse Treatment

View full text Add to dashboard Cite

The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders

Cited by 4 publications

References 60 publications

COVID-19 and treating incarcerated populations for opioid use disorder

COVID-19 and treating incarcerated populations for opioid use disorder

Impact of COVID-19 pandemic on chronic pain and opioid use in marginalized populations: A scoping review

Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

Contact Info

Product

Resources

About

The Natural History, Clinical Course, and Long-Term Recovery from Opioid Use Disorders

Cited by 4 publications

References 60 publications

COVID-19 and treating incarcerated populations for opioid use disorder

COVID-19 and treating incarcerated populations for opioid use disorder

Impact of COVID-19 pandemic on chronic pain and opioid use in marginalized populations: A scoping review

Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder

Contact Info

Product

Resources

About

Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder